Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

"The SGR is a transformative project for Kisumu and the entire western Kenya region. This extension will bring much-needed ...

J.P. Morgan and Starwood Property Trust have provided $2 billion in financing for a data center project in West Jordan, located just south of Salt Lake City. The borrower, a partnership between Los ...

Israel is due to send a delegation to Qatar on Monday for a fresh round of talks on extending a fragile ceasefire in Gaza, ...

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

Holi, a prominent Hindu festival, will be celebrated on March 13 and 14, 2025. Holika Dahan, held on the first day, signifies ...

An elongated trough over British Columbia is splitting apart today with a cold front boundary slowly moving southeast. The main weather concerns associated with this system will be breezy to ...

SPK-9001 was licensed by Pfizer from Spark Therapeutics pursuant to a December 2014 agreement, under which Spark was responsible for conducting all phase 1 and 2 studies for the gene therapy.